A bacteriocin-based treatment option for Staphylococcus haemolyticus biofilms

Area of Science:

• Microbiology
• Biochemistry
• Drug Discovery

Background:

• Bacteriocins are antimicrobial peptides with potential against multidrug-resistant pathogens.
• Novel therapeutic strategies are needed to combat nosocomial infections caused by bacteria like Staphylococcus haemolyticus.

Purpose of the Study:

• To design and evaluate a novel hybrid bacteriocin (H1) with enhanced antimicrobial properties.
• To assess the efficacy of a multi-component bacteriocin formulation against Staphylococcus haemolyticus, including biofilm eradication and resistance prevention.

Main Methods:

• Construction of a hybrid bacteriocin (H1) by combining elements of enterocin K1 and enterocin EJ97.
• Antimicrobial activity testing of H1 against clinical and commensal Staphylococcus haemolyticus strains.
• Evaluation of a three-component bacteriocin formulation (H1, micrococcin P1, garvicin KS) against planktonic and biofilm-associated Staphylococcus haemolyticus, and assessment of resistance development.

Main Results:

• The hybrid bacteriocin H1 demonstrated superior antimicrobial activity against Staphylococcus haemolyticus, including all tested clinical and commensal strains.
• The three-component bacteriocin formulation was highly effective against planktonic cells and completely eradicated biofilm-associated Staphylococcus haemolyticus in vitro.
• The formulation significantly prevented the development of resistant mutants.

Conclusions:

• Hybrid bacteriocin H1 is a promising candidate for targeting Staphylococcus haemolyticus.
• A multi-component bacteriocin formulation offers a potent strategy for combating Staphylococcus haemolyticus infections, including biofilms, and preventing resistance.
• Bacteriocin-based formulations represent a viable therapeutic approach for challenging bacterial pathogens.